Research paper

2-Chlorohexadecanoic acid induces ER stress and mitochondrial dysfunction in brain microvascular endothelial cells

Eva Bernhart, Nora Kogelnik, Jürgen Prasch, Benjamin Gottschalk, Madeleine Goeritzer, Maria Rosa Depaoli, Helga Reicher, Christoph Nusshold, Ioanna Plastira, Astrid Hammer, Günter Fauler, Roland Malli, Wolfgang Graier, Ernst Malle

Gottfried Schatz Research Center for Signaling, Metabolism and Aging, Molecular Biology and Biochemistry, Medical University of Graz, Austria
BioTechMed Graz, Austria
Institute of Physiological Chemistry, Medical University of Graz, Austria
Gottfried Schatz Research Center for Signaling, Metabolism and Aging, Cell Biology, Histology and Embryology, Medical University of Graz, Austria
Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Austria

ARTICLE INFO

Keywords:
Apoptosis
Blood-brain barrier
Lipotoxicity
Myeloperoxidase
Neuroinflammation
Structured illumination microscopy

ABSTRACT

Peripheral leukocytes induce blood-brain barrier (BBB) dysfunction through the release of cytotoxic mediators. These include hypochlorous acid (HOCl) that is formed via the myeloperoxidase-H2O2-chloride system of activated phagocytes. HOCl targets the endogenous pool of ether phospholipids (plasmalogens) generating chlorinated inflammatory mediators like e.g. 2-chlorohexadecanal and its conversion product 2-chlorohexadecanoic acid (2-ClHA). In the cerebrovasculature these compounds inflict damage to brain microvascular endothelial cells (BMVEC) that form the morphological basis of the BBB. To follow subcellular trafficking of 2-ClHA we synthesized a ‘clickable’ alkyne derivative (2-ClHyA) that phenocopied the biological activity of the parent compound. Confocal and superresolution structured illumination microscopy revealed accumulation of 2-ClHyA in the endoplasmic reticulum (ER) and mitochondria of human BMVEC (hCMEC/D3 cell line). 2-ClHA and its alkyne analogue interfered with protein palmitoylation, induced ER-stress markers, reduced the ER ATP content, and activated transcription and secretion of interleukin (IL)−6 as well as IL-8. 2-ClHA disrupted the mitochondrial membrane potential and induced procaspase-3 and PARP cleavage. The protein kinase R-like ER kinase (PERK) inhibitor GSK2606414 suppressed 2-ClHA-mediated activating transcription factor 4 synthesis and IL-6/8 secretion, but showed no effect on endothelial barrier dysfunction and cleavage of procaspase-3. Our data indicate that 2-ClHA induces potent lipotoxic responses in brain endothelial cells and could have implications in inflammation-induced BBB dysfunction.

1. Introduction

The neurovascular unit separates most regions of the brain from the peripheral circulation to maintain the specialized central nervous system (CNS) micromilieu [1]. Brain microvascular endothelial cells (BMVEC) form the morphological basis of the blood-brain barrier (BBB) by the formation of tight junction (TJ) and adherens junction complexes [2]. These junctional complexes inhibit paracellular leakage and maintain CNS homeostasis via polarized expression of transporter systems taking a central biochemical gate-keeping function at the BBB [3,4].

Under inflammatory conditions BBB function is compromised and

Abbreviations: HA, hexadecan-1-oic (palmitic) acid; HyA, hexadec-15-yn-1-oic acid; 2-ClHDA, 2-chlorohexadecanal; 2-ClHyA, 2-chlorohexadec-15-yn-1-oic acid
⁎ Corresponding author.
⁎⁎ Corresponding author at: Institute of Molecular Biology and Biochemistry, Medical University of Graz, Austria.
E-mail addresses: eva.bernhart@medunigraz.at (E. Bernhart), nora.kogelnik@medunigraz.at (N. Kogelnik), j.prasch@medunigraz.at (J. Prasch), benjamin.gottschalk@medunigraz.at (B. Gottschalk), madeleine.goeritzer@medunigraz.at (M. Goeritzer), m.depaoli@medunigraz.at (M.R. Depaoli), helga.reicher@medunigraz.at (H. Reicher), christoph.nusshold@medunigraz.at (C. Nusshold), ioanna.plastira@medunigraz.at (I. Plastira), astrid.hammer@medunigraz.at (A. Hammer), guenter.fauler@medunigraz.at (G. Fauler), roland.malli@medunigraz.at (R. Malli), wolfgang.graier@medunigraz.at (W.F. Graier), ernst.malle@medunigraz.at (E. Malle), wolfgang.sattler@medunigraz.at (W. Sattler).
1 equal contribution.

https://doi.org/10.1016/j.redox.2018.01.003
Received 12 December 2017; Received in revised form 29 December 2017; Accepted 4 January 2018
Available online 05 January 2018
2213-2317/ © 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).
can aggravate neuronal dysfunction [5]. Many of the pathways that interfere with BBB and neuronal function converge on the formation of reactive species [6]. This is of importance since TJ proteins are sensitive to alterations of the intracellular redox status [7] and oxidative stress induces a downregulation of the TJ protein occludin and disrupts the cadherin-catenin complex in brain endothelial cells [8]. In cerebrovascular diseases and stroke reactive oxygen species (ROS) can inhibit cerebral blood flow and impact barrier function [9–12]. Additionally, oxidative stress-induced activation of matrix metalloproteinases (MMPs) and fluid channel aquaporins promote leakiness of the BBB and vascular edema [13].

During earlier work we could show pronounced BMVEC barrier dysfunction in response to the chlorinated fatty aldehyde 2-chlorohexadecanal (2-CHDA) that is generated during endotoxemia [14,15]. 2-CHDA is formed through attack of plasmalogens (ether phospholipids) by hypochlorous acid/hypochlorite (HOCl/OCl-) [16,17] generated via the myeloperoxidase (MPO)-H2O2-Cl system of activated phagocytes [18]. Under physiological conditions MPO is part of the innate immune system [19], however, under chronic inflammatory conditions MPO is considered a disease modifier [20]. MPO-derived oxidants have been shown to contribute to atherosclerosis and plaque instability [21–23], cardiac dysfunction [24], or diseases with a neuroinflammatory component [25]. The involvement of MPO in barrier dysfunction was also demonstrated during bacterial meningitis [26,27]. MPO is expressed in demyelinated lesions in Multiple Sclerosis (MS) in humans and rodents [28]. In line, pharmacological inhibition of MPO reduced the severity of clinical symptoms in a murine MS model [29]. In response to systemic lipopolysaccharide (LPS) administration MPO levels in mouse brain are elevated and accompanied by decreased brain plasmalogen content and concomitant formation of 2-CHDA [14]. In line with deleterious effects of MPO-generated 2-CHDA [15], the MPO inhibitor N-acetyl l-lysytrosylcysteine amide ameliorates brain damage in a murine model of stroke [30] and counteracts BBB damage in a murine model of MS [31].

The electrophile 2-CHDA impairs protein function by covalent modification, thereby triggering cytotoxic and adaptive responses that are typically associated with oxidative stress [32]. Consequentially, conversion of (reactive) aldehydes to their corresponding alcohol and/or carboxylic acid analogues via the fatty alcohol cycle was considered as a protective pathway [33]. The Ford group has first demonstrated that
2-CHDA is oxidized to 2-chlorohexadecanoic acid (2-CHDA) within this metabolic pathway [34]. The same group has shown that 2-CHDA accumulates in activated monocytes and induces apoptosis through ROS formation and endoplasmic reticulum (ER) stress pathways [35].

During the present study we synthesized and analytically characterized an alkyne derivative of 2-CHDA, namely 2-chlorohexadec-15-yn-1-oic acid (2-CHHyA) that is accessible to copper-catalyzed cycloaddition reactions. We investigated subcellular distribution using conventional confocal laser scanning microscopy and superresolution structured illumination microscopy (SIM), followed by characterization of ER- and mitochondria-specific cellular responses. Our data identify 2-CHDA as an inflammatory lipid mediator that interferes with protein palmitoylation and compromises ER- and mitochondrial functions in the human brain endothelial cell line hCMEC/D3.

2. Material and methods

A detailed Materials and Methods section describing synthetic and analytical procedures, cell culture, MTT and ECIS analyses, click-chemistry and subcellular colocalization studies [32], ATP measurements [36], metabolic labelling procedures, Western, FACS and qPCR analyses, ELISA and statistical data analysis is provided in the SUPPLEMENT.

3. Results

As a first step we synthesized 2-CHDA and 2-CHHyA containing a terminal alkyne group suitable as click-chemistry scaffold [32]. 2-CHDA and the clickable orthologue 2-CHHyA were synthesized from 2-CHDA or 2-CHHyA using oxone as the oxidant [37]. The resulting products were characterized by NCI-GC-MS as FBF-ester derivatives (structures given in Fig. 1A and B, upper panels). The FBF-esters eluted as single peaks under the analytical conditions used (Fig. 1A and B, middle panels). The molecular ions (M) at m/z 469.9 and 465.9 were unetectable under the analytical conditions used (Fig. 1A and B, middle panel as loading control). In these experiments target proteins of different molecular mass were labelled. Coomassie stained gels (to account for equal loading) are shown in the middle panels. Quantitation of fluorescence intensities (Fig. 3A; lower panel) indicates that in the presence of equimolar 2-CHDA concentrations protein acylation with HyA was reduced by 60% indicating that 2-CHDA interferes with protein palmitoylation. In a reverse experimental approach cells were labelled with 2-CHHyA (25 µM) and incorporation was competed with HA (5, 15, and 25 µM; Fig. 3B; upper panel). The Coomassie-stained gel is shown in the middle panel as loading control. In these experiments target protein labelling by 2-CHHyA was efficient but competition by HA was low (approx. 20% at 15 and 25 µM; Fig. 3B lower panel). This indicates covalent alkylation rather than formation of a labile thioether bond.

Aberrant protein palmitoylation induces ER stress, a pathway detrimental for brain endothelial barrier function [39]. Incubation of hCMEC/D3 cells with 2-CHDA resulted in phosphorylation of eIF2α starting 4 h post treatment, while total eIF2α levels remained unchanged (Fig. 4A). In line, expression of ATF4, a target gene of eIF2α, was increased by 2-CHDA when compared with untreated or vehicle-treated cells. In concert with eIF2α phosphorylation and upregulated ATF4 expression, 2-CHDA induced expression of the cell death executor CHOP. In parallel, expression of a central ER stress modulator and major chaperon, BiP (also termed GRP78) was upregulated after 24 h of cell treatment with 2-CHDA. Densitometric evaluation is shown in Fig. 5. Taken together, these results demonstrate that ER stress-related proteins are increased in response to 2-CHDA.

BiP contributes to protein folding by binding unfolded proteins in an ATP-dependent manner [40]. As 2-CHDA induced ER stress, we hypothesized that it also alters the ATP concentration within the ER lumen ([ATP]ER). To determine effects of 2-CHDA on [ATP]ER in single cells we used a genetically encoded ER targeted, Förster resonance energy transfer (FRET)-based ATP probe (ERAT), which was developed recently [36]. These measurements revealed that 2-CHDA (but not HA) induced a decrease in the FRET ratio signal of ERAT by 40%, indicating significantly diminished [ATP]ER in cells that were treated with 2-CHDA (Fig. 4B).

Inflammatory pathways in the CNS are linked to the ER stress response [41]. A previous study demonstrated the involvement of the pro-apoptotic transcription factor CHOP (an ATP4 target gene) in the regulation of pro-inflammatory cytokine secretion through intermediate NF-kB activation [42]. In line with this study, we found that treatment of hCMEC/D3 cells with 2-CHDA increased gene expression of IL-6 and IL-8 four- and forty-fold over baseline levels, respectively (Fig. 5A,B). Maximum upregulation of IL-6 was observed at 8 h while IL-8 was already fully induced at 4 h. Cytokine analysis in the cellular supernatants by ELISA confirmed the upregulation of IL-6 and IL-8 on protein level (Fig. 5C,D).

Unmitigated ER stress can induce mitochondrial dysfunction and culminate in apoptosis to eliminate irreversibly damaged cells via apoptotic pathways [43]. These pathways are linked to a disturbed mitochondrial Ca2+ homeostasis, disruption of the mitochondrial membrane potential, and activation of pro-apoptotic caspases [44]. Analysis of the mitochondrial membrane potential (Ψm) by cLSM using TMRM demonstrated that 2-CHDA caused a depolarization of Ψm indicating the induction of mitochondrial dysfunction (Fig. 6A).

To detect potential pro-apoptotic effects vehicle and 2-CHDA-treated cells were stained with Annexin V/PI and analyzed by flow cytometry. DMSO was without effect on early and late apoptosis, while 2-CHDA increased the percentage of early apoptotic cells from 24.7% to 47.6%; in parallel late apoptotic cells increased from 14% to 23% (scatter plots...
Fig. 2. 2-ClHyA is detected in the ER and mitochondria of hCMEC/D3 cells. (A) Cells were treated with 2-ClHyA (25 µM, 30 min), fixed with para-formaldehyde, permeabilized with Triton X-100 and clicked with N3-TAMRA. ER-labelling was performed with anti-calnexin antibody (1:100 in antibody diluent; 4 °C over night). Alexa 488-labelled goat anti-rabbit (1:300 in antibody diluent) was used as secondary antibody. Cells were visualized by cLSM. (B) Cells were transfected with a FRET-based ER-targeted ATP sensor plasmid (ERAT4.01) and then treated with 2-ClHyA as described in (A). Cells were fixed, permeabilized, clicked with N3-TAMRA and visualized by SIM. (C, D) Cells were treated with 2-ClHyA as described in (A) and then incubated with anti-COX IV antibody (1:100 in antibody diluent, 4 °C overnight). Alexa 488-labelled goat anti-rabbit (1:300 in antibody diluent) was used as secondary antibody. Cells were visualized by cLSM (C) or SIM (D).
are shown in Fig. S3; statistical evaluation in Fig. 6B). In line, 2-ClHA activated caspase-3 (Fig. 6C), the convergence point of the extrinsic and intrinsic apoptotic machinery [45] and induced PARP cleavage (Fig. 6D; densitometric evaluations and statistical analyses are shown in Fig. S4). The final set of experiments aimed to test whether pharmacological antagonism of PERK could suppress the inflammatory response and inhibit the induction of apoptosis. Therefore, hCMEC/D3 cells were preincubated with increasing GSK2606414 concentrations (0.01, 0.1, and 1 µM) and then received vehicle or 2-ClHA. Expression of ATF4 (which is downstream of PERK and induces pro-apoptotic CHOP) was followed by Western blot analysis. 2-ClHA-mediated ATF4 induction was attenuated by 1 µM GSK2606414 (Fig. 7A, densitometric evaluation in right bar graph). Real-time qPCR analyses demonstrated that GSK2606414 attenuated 2-ClHA-induced gene expression of IL-6 and IL-8 (Fig. 7B). GSK2606414 treatment also reduced IL-6 and IL-8 protein levels in the cellular supernatants (Fig. 7C). Finally, we addressed the question whether PERK inhibition can restore 2-ClHA-induced cell monolayer disintegration. Surprisingly, GSK2606414 did neither mitigate barrier dysfunction (Fig. 7D) nor pro-caspase-3 processing (Fig. 7E).

4. Discussion

MPO-mediated plasmalogen modification at the cerebrovascular interface results in the generation of reactive species including chlorinated fatty aldehydes and -acids that compromise cell [15,32,35,46] and organ [22,24] homeostasis. In the present study we have identified uptake of 2-ClHyA into the ER and mitochondria of brain endothelial cells. 2-ClHA interfered with palmitoylation, induced unresolved ER stress and mitochondrial dysfunction, culminating in apoptosis. Our data are in line with the fact that fatty acids are potent inducers of cell stress in the inflamed endothelium [47].

Although ample evidence indicates that MPO-derived oxidants play an important role in endothelial dysfunction [48] physiological relevance of 2-ClHA-induced BMVEC dysfunction is a major question arising from our in vitro study. The Ford group has shown that 2-chlorofatty acid levels in plasma of patients suffering from sepsis-
Fig. 4. 2-ClHA induces ER stress depletion of [ATP]_{ER} in hCMEC/D3 cells. (A) Serum starved cells were incubated in the absence (c) or presence of DMSO (0.1%, vehicle control, vc) and 2-ClHA (10 µM) for the indicated time points. Total cell lysates were subjected to SDS-PAGE. Antibodies against p-eIF2α, eIF2α, ATF4, CHOP, and BiP were used as primary antibodies. β-Actin was used as loading control. For each protein one representative blot out of three independent experiments is shown. Densitometric and statistical evaluation of Western blot results is shown in Fig. S2. (B) Cells expressing ERAT4.01 were cultured in the absence (c), or presence of HA (25 µM; 30 min) or 2-ClHA (both 25 µM, 30 min) and the FRET ratio was acquired on a Zeiss AxioVert inverted microscope. Columns represent ratio signals of ERAT4.01 obtained for the respective treatment conditions. At least 28 cells were analyzed in two independent experiments.

Fig. 5. 2-ClHA induces IL-6 and IL-8 gene and protein expression in hCMEC/D3 cells. (A,B) Serum-starved cells were incubated in the absence (c) or presence of DMSO (0.1%, vehicle control, vc) and 2-ClHA (10 µM) for the times indicated and gene expression of IL-6 (A) and IL-8 (B) was evaluated by qPCR analysis. Hprt was used as the housekeeping gene. Data shown are normalized to ‘vc’ and represent mean ± SD from 3 independent experiments performed in triplicates. Expression profiles were calculated using the 2^(-DDCT) method. (C,D) Cells were treated as in (A) and IL-6 (C) and IL-8 (D) concentrations were quantitated in the cellular supernatants by ELISA. Results shown represent mean ± SD from three independent experiments performed in triplicate. *, p < 0.05; ***, p < 0.001; one-way ANOVA with Bonferroni correction.
associated acute respiratory distress syndrome are higher as compared to the control group (median concentrations 1.12 vs. 0.43 nM) [49]. At higher concentrations (up to 10 µM as used during the present study) 2-ClHA reduced pulmonary endothelial cell barrier function in vitro by approx. 25%. This observation was accompanied by enhanced cell adhesion molecule expression and increased neutrophil and platelet adhesion [49]. However, it is important to note that the experiments described in [49] were performed in serum-containing medium (5%). Therefore the serum-free conditions used during the present study could generate a more ‘cytotoxic’ milieu since no 2-ClHA is bound by serum constituents e.g. S-alkylation reactions.

Septic encephalopathy is a multifactorial syndrome, which is characterized as diffuse brain dysfunction in humans [50] and associated with neutrophil accumulation and BBB dysfunction in mice [51]. Our group could demonstrate that LPS-induced BBB dysfunction is accompanied by a decrease in plasmalogens while the corresponding MPO-derived oxidation product 2-ClHDA accumulated in brains of LPS-injected mice at a concentration up to 10 µM [14]. This is most probably a result of neutrophil accumulation and MPO release in the cerebrovasculature of mice in response to a systemic LPS injection [15]. Within this pathophysiological setting, BMVEC-adhering leukocytes could affect endothelial function via 2-ClHA production since both neutrophils and monocytes are able to produce high concentrations (in vitro up to 20 µM) of 2-ClHA [34,35]. Finally, primary BMVEC and the hCMEC/D3 cell line used during the present study are able to convert exogenous 2-ChlHDA to 2-ClHA [32,52].

To determine intracellular localization of 2-ClHA we synthesized an alkyne-containing 2-ClHA analogue that allows covalent attachment of N3-containing reporter fluorophores by copper-catalyzed Huisgen 1,3-dipolar cycloaddition. During the synthesis of 2-ClHA or 2-ChlHyA we utilized oxone, an oxidant offering several advantages (one step-one pot reaction, non-toxic, low cost reagent) over hazardous chromium(VI)-based systems like the highly toxic pyridinium dichromate [37,53]. This synthetic route (starting from the corresponding aldehyde precursors 2-ChlHDA or 2-ChlHyA, respectively) is straightforward, proceeds at moderate conditions (RT, 3 h) and the reaction yield and purity of the product is feasible (both > 95%).

Subcellular localization of 2-ChlHyA was determined by N3-TAMRA click-chemistry and subsequent visualization of compartment-specific markers by cLSM and SIM. These experiments revealed uptake of 2-ChlHyA in the ER and mitochondria, raising the question of intracellular trafficking routes for this chlorinated fatty acid. Fatty acid transport proteins (FATP) are members of the Slc27 protein family with intrinsic acyl CoA synthase activity [54]. In the brain endothelium several membrane-associated FATPs were identified with highest expression reported for FATP-1, −4, and fatty acid translocase/CD36 [55]. In human carcinoma and canine kidney cells a major fraction of FATP4 was detected at the ER [56,57]. In terms of mitochondrial 2-ClHA
transport carnitine palmitoyltransferase 1 (CPT-1) and carnitine acyl-
carnitine translocase could facilitate mitochondrial import. Only re-
cently the Ford group has shown that 2-ClHyA is localized to Weibel-
Palade bodies and promotes the release of P-selectin, van Willebrand
factor, and angiopoietin in human aortic endothelial cells [53].

ER and mitochondrial function play a critical role in

E. Bernhart et al.  Redox Biology 15 (2018) 441–451

448
neurodegenerative diseases. Although the crosstalk underlying ER stress-induced apoptosis is not completely understood, evidence suggests that cell survival vs. cell death decisions depend on mitochondrial Ca2+ handling [43]. Aberrant protein palmitoylation is implicated in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease, Huntington's disease, or schizophrenia [58], and induces unresolved ER stress that culminates in cell death [59]. Pharmacological interference with S-palmitoylation is routinely performed with 2-BrHA, a chemical tool that inhibits palmitoyl acyl transferases but targets also other proteins by covalent alkylation [38, 60]. This is reminiscent of findings obtained during the present study: Using 2-ClHyA as activity-based probe, efficient protein labelling and only weak competition by HA was observed, findings that are compatible with non-specific covalent modification of target proteins (Fig. 3). This reaction most likely proceeds via chlorine abstraction at C2 and results in the formation of an irreversible and stable thioether adduct as described for 2-BrHyA [60]. Among 2-BrHA-modified proteins Davda and colleagues identified CPT-1 supporting mitochondrial accumulation of halogenated fatty acids [38] as also observed during the present study.

The ER depends on continuous supply of ATP to fulfill its biological functions [61]. Among these is the unfolded protein response that, under conditions of unresolved ER stress, represses an adaptive response and triggers apoptosis through activation of CHOP. Here, 2-ClHyA upregulated the canonical PERK axis, namely elF2α, ATF4, and CHOP, and decreased [ATP]ER. These findings were accompanied by Ψm dissipation. Altered Ca2+ homeostasis and dissipation of Ψm contributes to the opening of the mitochondrial permeability transition pore, which facilitates cytochrome c efflux-driven assembly of the apoptosis [45]. In line we observed increased pro-caspase-3 and PARP processing. This is reminiscent of what was reported for phorbolester-stimulated monocytes: In these cells 2-ClHA accumulates in response to activation and elicits apoptosis through generation of reactive oxygen species and ER stress [35].

In addition to ER stress 2-ClHA increased IL-6 and IL-8 on the mRNA and protein level. In vitro, IL-6 induces barrier dysfunction and increases IL-8 synthesis in human brain endothelial cells [62] as observed here in 2-ClHA-treated hCMEC/D3 cells. ER stress may contribute to sustained production of inflammatory mediators obstructing resolution of inflammation, a condition relevant to infectious, metabolic, and neurodegenerative diseases [63]. Human aortic endothelial cells upregulate synthesis of IL-6 and IL-8 in response to oxidized phospholipids in a PERK-dependent manner [64]. Of note, this class of oxidized lipids is not only detectable in atherosclerotic lesions [65] but also in brain of MS patients [66] and other settings of neurodegeneration [67]. Thus, blocking the inflammatory response through PERK inhibition could have pharmacological relevance in neurodegenerative diseases where ER stress is prevalent [43]. During the present study we used GSK2606641A (that also inhibits RIPK1; Ref. [68]) as PERK antagonist to reveal whether this compound would rescue 2-ClHA-induced brain endothelial dysfunction. We observed decreased ATF4 expression in response to GSK2606641A that also blunted the inflammatory response of BMVEC. However, GSK2606641A was without effect on pro-caspase-3 processing and associated barrier leakiness. This is reminiscent of what was reported for a panel of other ER stress inhibitors in Ap1–40 treated rat brain endothelial cells [39].

In summary we identified 2-ClHA as an MPO-generated inflammatory trigger that induces ER stress and apoptosis in BMVEC. Our findings suggest that 2-chlorofatty acid generation during cerebrovascular inflammation holds potential to induce BBB dysfunction probably due to the local accumulation of these cytotoxic lipids in cellular organelles.

Acknowledgements

Expert technical assistance was provided by Anja Feiner. Financial support was provided by the Austrian Science Fund (DK MOLIN-W1241), the Medical University of Graz (N.K. within DK-W1241), and BioTechMed Graz (to M.G., R.M., W.F.G., and W.S.). The funding organizations were not involved in study design or in collection, analysis and interpretation of data.

Disclosures

None.

Author contributions

Conception and design of the study: E.B., N.K., R.M., W.F.G., E.M., W.S.

Acquisition of data, analysis and interpretation of data: E.B., N.K., J.P., B.G., M.G., M.R.D., H.R., C.N., I.P., A.H., G.F.

DRAFTING/REVISION OF MANUSCRIPT: E.B., N.K., M.G., I.P., R.M., W.F.G., E.M., W.S.

Final approval of the manuscript: All authors.

Appendix A. Supplementary material

Supplementary data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.redox.2018.01.003.

References

[1] B.V. Zlokovic, The blood-brain barrier in health and chronic neurodegenerative disorders, Neuron 57 (2008) 178–201.

[2] B.T. Hawkins, T.P. Davis, The blood-brain barrier/neurovascular unit in health and disease, Pharmacol. Rev. 57 (2005) 173–185.

[3] S. Tsukita, M. Furuse, M. Itoh, Multifunctional strands in tight junctions, Nat. Rev. Mol. Cell Biol. 2 (2001) 285–293.

[4] B.V. Zlokovic, Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders, Nat. Rev. Neurosci. 12 (2011) 723–738.

[5] C. Coisne, B. Engelhardt, Tight junctions in brain barriers during central nervous system inflammation, Antioxid. Redox Signal. 15 (2011) 1285–1303.

[6] L.R. Freeman, J.N. Keller, Oxidative stress and cerebral endothelial cells: regulation of the blood-brain-barrier and antioxidant based interventions, Biochim. Biophys. Acta 1822 (2012) 822–829.

[7] I.E. Blasig, C. Bellmann, J. Cording, G. Del Vecchio, D. Zwanziger, O. Huber, R.F. Haseloff, Occludin protein family: oxidative stress and reducing conditions, Antioxid. Redox Signal. 15 (2011) 1195–1219.

[8] I.A. Krizbai, H. Bauer, N. Bresch, P.M. Eckl, A. Farkas, E. Szatmari, A. Trauwerg, K. Węska, H.C. Bauer, Effect of oxidative stress on the junctional proteins of cultured cerebral endothelial cells, Cell Mol. Neurobiol. 25 (2005) 129–139.

[9] S. Chrousos, F.M. Faraci, The role of oxidative stress and NAPDH oxidase in cerebrovascular disease, Trends Mol. Med. 14 (2008) 495–502.
A.K. Thukkani, B.D. Martinson, C.J. Albert, G.A. Vogler, D.A. Ford, Neutrophil-mediated accumulation of 2-ClHDA during myocardial infarction: 2-clhda-mediated effects on the endoplasmic reticulum (er) and beyond, Nat. Rev. Mol. Cell Biol. 13 (2012) 477–491.

A. Forghani, G.R. Wojtkiewicz, Y. Zhang, D. Seeburg, B.R. Bautz, B. Pulli, J. McHowat, D.A. Ford, Chlorinated lipid species in activated human neutrophils: lipid metabolites of 2-chlorohexadecanal, J. Lipid Res. 51 (2010) 152–166.

A. Snumer, A. Ullen, N. Kogelnik, E. Bernhart, H. Reicher, I. Plastira, T. Glasnov, R. T. Kennedy, B.R. Martin, Profiling targets of the irreversible pimaylomation inhibitor 2-bromomaleic anhydride, ACS Chem. Biol. 8 (2013) 191–199.

C. Hetz, S. Saxena, ER stress and the unfolded protein response in neurodegeneration, Nat. Rev. Neurol. 13 (2017) 477–491.

S.J. Klebanoff, A.J. Hettle, R. Winter, C.C. Winterbourn, W.W. Nau, Myeloperoxidase: a front-line defender against phagocytosed microorganisms, J. Leukoc. Biol. 93 (2013) 185–198.

A. N. Teng, G.J. Maghzal, J. Talib, I. Rashid, A.K. Lau, R. Stocker, The roles of myeloperoxidase involvement in multiple sclerosis, J. Neuroimmunol. 78 (1997) 177–185.

K. Kisler, A.R. Nelson, A. Montagne, B.V. Zlokovic, Cerebral blood ischaemic stroke, Int. J. Stroke 4 (2009) 461–466.

S.Y. Zhang, A. Ray, N.M. Miller, D. Hartwig, K.A. Pritchard Jr., B.N. Dittel, Inhibition of myeloperoxidase oxidant production by N-acetyl lysyltyrosylcysteine amide reinforces blood-brain-barrier integrity and ameliorates disease severity, J. Neurochem. 13 (2016) 7085–7095.

S.L. Leib, M.G. Tauber, Oxidative stress in brain during experimental bacterial meningitis, Nature Rev. Immunol. 4 (2004) 1637–1641.

S.J. Klebanoff, S.S. Sims, C.L. Sanchez, G.P. Meares, Endoplasmic reticulum stress-activated C/EBP homologous protein enhances nuclear factor-kappab signaling via repression of pereoxisome proliferator-activated receptor gamma, J. Biol. Chem. 285 (2010) 35330–35339.

C. Hetz, S. Saxena, ER stress and the unfolded protein response in neurodegeneration, Nat. Rev. Neurol. 13 (2017) 477–491.

S.J. Klebanoff, S.S. Sims, C.L. Sanchez, G.P. Meares, Oxidative stress in the central nervous system, Mol. Neurodegener. 12 (2017) 42.

S. Green, L.K. Scott, A. Minagar, S. Conrad, Sepsis associated encephalopathy (SAE): a review, Front. Biosci. 9 (2004) 1637–1641.

S.H. Huang, F. Chi, L. Peng, T. Be, B. Zhang, L.Q. Lin, X. Wu, N. Mor-Vaknin, D.M. Markovitz, H. Cao, Y.H. Zhou, Vimentin, a novel NF-kappab regulator, is required for meningitic escherichia coli K1-Induced pathogen Invasion and PMN transmigration across the Blood-Brain Barrier, PLoS One 11 (2016) e0162641.

H. Zhang, A. Ray, N.M. Miller, D. Hartwig, K.A. Pritchard Jr., B.N. Dittel, Inhibition of myeloperoxidase oxidant production by N-acetyl lysyltyrosylcysteine amide reinforces blood-brain-barrier integrity and ameliorates disease severity, J. Neurochem. 13 (2016) 7085–7095.
[63] K. Zhang, R.J. Kaufman, From endoplasmic-reticulum stress to the inflammatory response, Nature 454 (2008) 455–462.

[64] P.S. Gargalovic, N.M. Gharavi, M.J. Clark, J. Pagnon, W.P. Yang, A. He, A. Truong, T. Baruch-Oren, J.A. Berliner, T.G. Kirchgessner, A.J. Lusis, The unfolded protein response is an important regulator of inflammatory genes in endothelial cells, Arterioscler. Thromb. Vasc. Biol. 26 (2006) 2490-2496.

[65] E.A. Podrez, E. Poliakov, Z. Shen, R. Zhang, Y. Deng, M. Sun, P.J. Finton, L. Shan, M. Febbraio, D.P. Hajjar, R.L. Silverstein, H.F. Hoff, R.G. Salomon, S.L. Hazen, A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions, J. Biol. Chem. 277 (2002) 38517-38523.

[66] J. Qin, R. Goswami, R. Balabanov, G. Dawson, Oxidized phosphatidylcholine is a marker for neuroinflammation in multiple sclerosis brain, J. Neurosci. Res. 85 (2007) 977–984.

[67] B. Halliwell, Oxidative stress and neurodegeneration: where are we now? J. Neurochem. 97 (2006) 1634-1658.

[68] D. Rojas-Rivera, T. Delvaeye, R. Roelandt, W. Nerinckx, K. Augustyns, P. Vandenabeele, M.J.M. Bertrand, When PERK inhibitors turn out to be new potent RIPK1 inhibitors: critical issues on the specificity and use of GSK2606414 and GSK2656157, Cell Death Differ. 24 (2017) 1100-1110.